Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Cx43 agonistic monoclonal antibody ALMB-0168

A humanized agonistic monoclonal antibody targeting connexin43 (Cx43; gap junction alpha-1 protein) hemichannels, with potential antineoplastic activity. Upon administration, Cx43 agonistic monoclonal antibody ALMB-0168 binds to the extracellular domain of Cx43 and activates the Cx43 hemichannels expressed on osteocytes, but not those in gap junctions. This causes the Cx43 hemichannels to open and release several factors including adenosine triphosphate (ATP) into the extracellular environment in the bone and tumor-inhibiting cytokines. This may inhibit tumor cell growth and migration in the bone. Cx43, mechanosensitive hemichannels highly expressed in osteocytes, plays important roles in osteocytes functions by mediating the release of various signaling molecules.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:connexin43 agonistic monoclonal antibody ALMB-0168
connexin43 hemichannel monoclonal antibody ALMB-0168
connexin43 hemichannel-activating monoclonal antibody ALMB-0168
Code name:ALMB 0168
ALMB-0168
ALMB168
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search